# Anamorelin

Canonical source: https://retacompare.com/encyclopedia/anamorelin

Oral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.

Reference facts

Also known asONO-7643, RC-1291, AdlumizCategoryGrowth Hormone & GhrelinMechanism of actionOral GHS-R1a agonist that stimulates appetite, GH/IGF-1 axis and lean body mass.TargetsGHS-R1aIndications under research or approvedCancer cachexia (NSCLC, gastric, pancreatic, colorectal)Regulatory status (reference entry)Approved Japan (Adlumiz, 2021); FDA CRL 2017Half-life~7 hoursSequence notesOrally active peptidomimetic ghrelin receptor agonist (small molecule with peptide-mimetic backbone).Molecular weight (Da)547Originator / sponsorHelsinn / OnoFirst reported2003
    Primary References

ROMANA-1/2 cachexia trials, Lancet Oncol 2016


    Explore research articles about Anamorelin


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- ROMANA-1/2 cachexia trials, Lancet Oncol 2016: https://pubmed.ncbi.nlm.nih.gov/26906526/